JP2019011344A5 - - Google Patents

Download PDF

Info

Publication number
JP2019011344A5
JP2019011344A5 JP2018176400A JP2018176400A JP2019011344A5 JP 2019011344 A5 JP2019011344 A5 JP 2019011344A5 JP 2018176400 A JP2018176400 A JP 2018176400A JP 2018176400 A JP2018176400 A JP 2018176400A JP 2019011344 A5 JP2019011344 A5 JP 2019011344A5
Authority
JP
Japan
Prior art keywords
virus
influenza
influenza virus
sia
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018176400A
Other languages
English (en)
Japanese (ja)
Other versions
JP7260270B2 (ja
JP2019011344A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019011344A publication Critical patent/JP2019011344A/ja
Publication of JP2019011344A5 publication Critical patent/JP2019011344A5/ja
Application granted granted Critical
Publication of JP7260270B2 publication Critical patent/JP7260270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018176400A 2006-09-11 2018-09-20 卵を使用しないインフルエンザウイルスワクチンの作製 Active JP7260270B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84372006P 2006-09-11 2006-09-11
US60/843,720 2006-09-11
US93627907P 2007-06-18 2007-06-18
US60/936,279 2007-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016021859A Division JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020028399A Division JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製

Publications (3)

Publication Number Publication Date
JP2019011344A JP2019011344A (ja) 2019-01-24
JP2019011344A5 true JP2019011344A5 (enrdf_load_stackoverflow) 2019-07-25
JP7260270B2 JP7260270B2 (ja) 2023-04-18

Family

ID=39184185

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2009527227A Active JP5954921B2 (ja) 2006-09-11 2007-09-11 卵を使用しないインフルエンザウイルスワクチンの作製
JP2016021859A Withdrawn JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製
JP2017038957A Pending JP2017101073A (ja) 2006-09-11 2017-03-02 卵を使用しないインフルエンザウイルスワクチンの作製
JP2018176400A Active JP7260270B2 (ja) 2006-09-11 2018-09-20 卵を使用しないインフルエンザウイルスワクチンの作製
JP2020028399A Withdrawn JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製
JP2021215388A Active JP7427648B2 (ja) 2006-09-11 2021-12-29 卵を使用しないインフルエンザウイルスワクチンの作製
JP2023074617A Pending JP2023093728A (ja) 2006-09-11 2023-04-28 卵を使用しないインフルエンザウイルスワクチンの作製

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2009527227A Active JP5954921B2 (ja) 2006-09-11 2007-09-11 卵を使用しないインフルエンザウイルスワクチンの作製
JP2016021859A Withdrawn JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製
JP2017038957A Pending JP2017101073A (ja) 2006-09-11 2017-03-02 卵を使用しないインフルエンザウイルスワクチンの作製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020028399A Withdrawn JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製
JP2021215388A Active JP7427648B2 (ja) 2006-09-11 2021-12-29 卵を使用しないインフルエンザウイルスワクチンの作製
JP2023074617A Pending JP2023093728A (ja) 2006-09-11 2023-04-28 卵を使用しないインフルエンザウイルスワクチンの作製

Country Status (12)

Country Link
US (3) US20100010199A1 (enrdf_load_stackoverflow)
EP (4) EP2497495B3 (enrdf_load_stackoverflow)
JP (7) JP5954921B2 (enrdf_load_stackoverflow)
KR (1) KR20090057015A (enrdf_load_stackoverflow)
AU (1) AU2007297178B2 (enrdf_load_stackoverflow)
BR (1) BRPI0716536A2 (enrdf_load_stackoverflow)
CA (2) CA3016948A1 (enrdf_load_stackoverflow)
EA (1) EA200970271A1 (enrdf_load_stackoverflow)
ES (3) ES2536401T3 (enrdf_load_stackoverflow)
MX (1) MX2009002408A (enrdf_load_stackoverflow)
NZ (1) NZ575271A (enrdf_load_stackoverflow)
WO (1) WO2008032219A2 (enrdf_load_stackoverflow)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2368572B1 (en) * 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN101553252A (zh) * 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
JP2012507272A (ja) * 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
EP2396031A1 (en) * 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
KR101825697B1 (ko) 2009-02-10 2018-02-05 노파르티스 아게 감소된 양의 스쿠알렌을 포함하는 인플루엔자 백신
EA201171032A1 (ru) * 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
DE102010018462A1 (de) * 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
CA2800182A1 (en) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
CN103764160A (zh) 2009-05-29 2014-04-30 诺华有限公司 流感病毒血凝素试验
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
WO2011014645A1 (en) 2009-07-30 2011-02-03 Mount Sinai School Of Medicine Of New York University Influenza viruses and uses thereof
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
AU2011217903B2 (en) 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2552479A4 (en) 2010-03-30 2015-03-04 Sinai School Medicine INFLUENZA VIRUS VACCINES AND USES THEREOF
CN101804203A (zh) * 2010-05-10 2010-08-18 洛阳普莱柯生物工程有限公司 一种大规模生产伪狂犬病毒疫苗的方法
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
WO2012033236A1 (ko) * 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
US9580761B2 (en) 2011-02-25 2017-02-28 Novartis Ag Exogenous internal positive control
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
CN102586195B (zh) * 2011-12-01 2013-09-04 哈药集团生物疫苗有限公司 一种利用Vero传代细胞制备禽流感病毒及其灭活疫苗的方法
US20140335507A1 (en) 2011-12-12 2014-11-13 Novartis Ag Assays for influenza virus hemagglutinins
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
KR102453351B1 (ko) * 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN110237246B (zh) * 2019-07-25 2022-11-15 北京鼎持生物技术有限公司 一种全悬浮细胞培养禽流感（h9）灭活疫苗的方法
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988430A (en) * 1975-02-10 1976-10-26 Hoffmann-La Roche Inc. Immunoassay of antipyrine
US4315906A (en) * 1979-05-21 1982-02-16 New England Nuclear Corporation Cold insoluble globulin, its purification and use
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8703696D0 (en) 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
UA32546C2 (uk) 1991-03-01 2001-02-15 Міннесота Майнінг Енд Мен'Юфекчурінг Компані 1,2-заміщені 1н-імідазо[4,5-с]хінолін-4-аміни, проміжні сполуки для їх синтезу, антивірусна фармацевтична композиція, спосіб лікування інфікованих ссавців, спосіб індукування біосинтезу інтерферону у ссавців, спосіб уповільнення росту бластом
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
BR9405957A (pt) 1993-03-23 1995-12-12 Smithkline Beecham Biolog Composições de vacina contendo lipidio A deacilatado 3-0 monofosforil
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
DE69937343T2 (de) 1998-05-07 2008-07-24 Corixa Corp., Seattle Adjuvanszusammensetzung und methoden zu deren verwendung
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
EP1150918B1 (en) 1999-02-03 2004-09-15 Biosante Pharmaceuticals, Inc. Method of manufacturing therapeutic calcium phosphate particles
JP4800485B2 (ja) 1999-03-26 2011-10-26 バイカル インコーポレイテッド ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法
CN1350578B (zh) 1999-04-06 2010-05-12 威斯康星校友研究基金会 用于疫苗和基因治疗的重组流感病毒
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2001004333A1 (en) 1999-07-14 2001-01-18 Mount Sinai School Of Medicine Of New York University In vitro reconstitution of segmented negative-strand rna viruses
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
DE60036952T2 (de) 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
RS50325B (sr) 1999-09-25 2009-09-08 University Of Iowa Research Foundation, Imunostimulatorne nukleinske kiseline
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
EP1317559B1 (en) 2000-04-28 2009-01-07 St. Jude Children's Research Hospital Dna transfection system for the generation of infectious negative strand rna virus
US6756383B2 (en) 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
CN100351249C (zh) 2000-09-11 2007-11-28 希龙公司 作为酪氨酸激酶抑制剂的喹啉酮衍生物
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
CA2438960A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
AU2002245636B2 (en) 2001-03-09 2004-10-14 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
EA013517B1 (ru) * 2001-07-02 2010-06-30 Эймско Лимитед Применение козьей сыворотки, полученной иммунизацией козы вич, для изготовления лекарственных средств
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
NZ533628A (en) 2001-11-27 2006-07-28 Anadys Pharmaceuticals Inc 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
PT1499311E (pt) 2002-03-29 2010-03-10 Novartis Vaccines & Diagnostic Benzazois substituídos e sua utilização como inibidores da raf cinase
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
CN1688573A (zh) 2002-08-23 2005-10-26 希龙公司 糖原合成酶激酶3的吡咯基抑制剂
CA2511646A1 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
JP5600375B2 (ja) * 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
ES2409782T3 (es) 2004-04-05 2013-06-27 Zoetis P Llc Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
DE602005024827D1 (de) 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
CN103555670B (zh) 2004-12-23 2015-08-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
EP1831357B1 (en) 2004-12-24 2012-10-17 Abbott Biologicals B.V. Rescue of influenza virus
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
EP1917352A4 (en) 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
US10655108B2 (en) 2005-11-01 2020-05-19 Seqirus UK Limited Cell-derived viral vaccines with low levels of residual cell DNA

Similar Documents

Publication Publication Date Title
JP2019011344A5 (enrdf_load_stackoverflow)
US7037707B2 (en) Method for generating influenza viruses and vaccines
CA2468957C (en) Methods of propagation of influenza virus in cell lines over expressing sialyl transferases
JP2015119730A5 (enrdf_load_stackoverflow)
WO2007132763A1 (ja) インフルエンザウイルスの増殖方法
WO2001064846A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
JP2009034115A5 (enrdf_load_stackoverflow)
RU2708151C2 (ru) Плазмиды и способ получения вирусных частиц
Shin et al. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines
EP2716752A1 (en) Canine influenza recombinant virus, preparation method therefor and application thereof
CN103118704B (zh) 经修饰的病毒株及用于改善流感病毒的疫苗种子的产生的方法
US20140377308A1 (en) METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES
KR102453351B1 (ko) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
WO2020004425A1 (ja) インフルエンザウイルスの培養方法
WO2020166524A1 (ja) 増殖方法
US20040142450A1 (en) Lung epithelial cell line for propagating viruses
CN1644686B (zh) 流感病毒哺乳动物细胞高产毒株、其重组毒株及其制备方法和应用
CN102234637B (zh) 重组甲型h1n1流感病毒灭活疫苗株(sc/pr8)的制备及应用
Mehrbod et al. Comparison of Vero and MDCK cell lines transfected with human siat7e gene for conversion to suspension culture
KR20190026663A (ko) 리소턴트 인플루엔자 바이러스 작출 방법
JP6748067B2 (ja) インフルエンザウイルス作出用細胞
CN104178457A (zh) 稳定共表达人源Siat7e和ST3GalIV的MDCK细胞系及用途
Vázquez Ramírez Process intensification for the production of MVA and influenza A virus in high density suspension cultures of AGE1. CR. pIX cells
Liu et al. Screening of a high growth influenza B virus strain in Vero cells
Elderfield et al. Using reverse genetics to improve influenza vaccines